Rechercher
image du produit
Lancet Oncology, The

S'abonner

Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial - 01/12/15

Doi : 10.1016/S1470-2045(15)00305-8 
Takehito Shukuya, MD a, Takeharu Yamanaka, ProfPhD b, Takashi Seto, MD c, Haruko Daga, MD d, Koichi Goto, MD e, Hideo Saka, MD f, Shunichi Sugawara, MD g, Toshiaki Takahashi, MD h, Soichiro Yokota, MD i, Hiroyasu Kaneda, MD j, Tomoya Kawaguchi, MD k, Seisuke Nagase, MD l, Tetsuya Oguri, MD m, Yasuo Iwamoto, MD n, Takashi Nishimura, MD o, Yoshihiro Hattori, MD p, Kazuhiko Nakagawa, ProfMD j, Yoichi Nakanishi, ProfMD q, Nobuyuki Yamamoto, Dr ProfMD r, ⁎
on behalf of the

West Japan Oncology Group

a Department of Respiratory Medicine, Juntendo University, Tokyo, Japan 
b Department of Biostatistics, Yokohama City University, Kanagawa, Japan 
c Department of Thoracic Oncology, National Kyushu Cancer Centre, Fukuoka, Japan 
d Department of Clinical Oncology, Osaka City General Hospital, Osaka, Japan 
e Department of Thoracic Oncology, National Cancer Centre Hospital East, Chiba, Japan 
f Department of Respiratory Medicine and Medical Oncology, National Hospital Organisation Nagoya Medical Centre, Aichi, Japan 
g Department of Pulmonary Medicine, Sendai Kousei Hospital, Miyagi, Japan 
h Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan 
i Department of Respiratory Medicine, National Hospital Organisation Toneyama National Hospital, Osaka, Japan 
j Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka, Japan 
k Department of Respiratory Medicine, Graduate School of Medicine, Osaka City University, Osaka, Japan 
l Department of Thoracic Surgery, Tokyo Medical University, Tokyo, Japan 
m Department of Respiratory Medicine, Allergy, and Clinical Immunology, Graduate School of Medical Sciences, Nagoya City University, Aichi, Japan 
n Department of Medical Oncology, Hiroshima City Hospital, Hiroshima, Japan 
o Department of Respiratory Medicine, Kyoto-Katsura Hospital, Kyoto, Japan 
p Department of Thoracic Oncology, Hyogo Cancer Center, Hyogo, Japan 
q Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan 
r Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan 

* Correspondence to: Dr Nobuyuki Yamamoto, Third Department of Internal Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, Wakayama, 641-8509, Japan Correspondence to: Dr Nobuyuki Yamamoto Third Department of Internal Medicine Wakayama Medical University 811-1 Kimiidera Wakayama Wakayama 641-8509 Japan

Summary

Background

The combination of nedaplatin, a cisplatin derivative, and docetaxel showed promising activity for advanced squamous cell lung carcinoma in a previous phase 1–2 study. We compared nedaplatin plus docetaxel with cisplatin plus docetaxel in patients with previously untreated advanced or relapsed squamous cell lung carcinoma to determine effects on overall survival.

Methods

We did a randomised, open-label, phase 3 study at 53 institutions in Japan. Eligibility criteria included pathologically proven squamous cell lung cancer with stage IIIB/IV or postoperative recurrence, age 20–74 years, Eastern Cooperative Oncology Group performance status of 0–1, no previous chemotherapy or recurrence more than a year after previous adjuvant chemotherapy, and adequate organ function. Patients were randomly assigned (1:1) to 100 mg/m2 nedaplatin and 60 mg/m2 docetaxel intravenously, or 80 mg/m2 cisplatin and 60 mg/m2 docetaxel, every 3 weeks for four to six cycles (at the treating oncologist’s discretion). Randomisation was done centrally at the West Japan Oncology Group data centre via a computer-generated allocation sequence with dynamic minimisation that balanced stage (IIIB/IV or postoperative recurrent), sex, and institution. The primary endpoint was overall survival in the modified intention-to-treat population (ie, all patients who were randomly assigned and met the inclusion criteria). Safety analyses were done in all randomly assigned patients who received at least one dose of the study regimen. This trial is registered with the UMIN Clinical Trials Registry, number UMIN000002015, and is closed to new participants.

Findings

Between July 6, 2009, and July 26, 2012, 355 patients were randomly assigned. 349 patients were included in the modified intention-to-treat analysis (177 in the nedaplatin group and 172 in the cisplatin group). Overall survival was significantly longer in the nedaplatin group (median 13·6 months, 95% CI 11·6–15·6) than in the cisplatin group (11·4 months,10·2–12·2; hazard ratio 0·81, 95% CI 0·65–1·02; p=0·037, one-sided stratified log-rank test). Grade 3 or worse nausea (seven of 177 patients in the nedaplatin group and 25 of 175 in the cisplatin group), fatigue (six vs 20), hyponatraemia (24 vs 53), and hypokalaemia (four vs 15) were more frequent in the cisplatin group than in the nedaplatin group, whereas grade 3 or worse leucopenia (98 vs 77), neutropenia (146 vs 123), and thrombocytopenia (16 vs none) were more frequent in the nedaplatin group than in the cisplatin group. Treatment-related deaths occurred in four and three patients in nedaplatin and cisplatin groups, respectively.

Interpretation

Overall survival was significantly longer with nedaplatin plus docetaxel than with cisplatin plus docetaxel, and the regimens had different safety profiles. Nedaplatin plus docetaxel could be a new treatment option for advanced or relapsed squamous cell lung cancer.

Funding

West Japan Oncology Group and Sanofi.

Le texte complet de cet article est disponible en PDF.

Plan


© 2015  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

    •

  • Contenu

    •

Vol 16 - N° 16

P. 1630-1638 - décembre 2015 Retour au numéro
Article précédent Article précédent
  • Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial
  • Francesca Gay, Stefania Oliva, Maria Teresa Petrucci, Concetta Conticello, Lucio Catalano, Paolo Corradini, Agostina Siniscalchi, Valeria Magarotto, Lud?k Pour, Angelo Carella, Alessandra Malfitano, Daniela Petrò, Andrea Evangelista, Stefano Spada, Norbert Pescosta, Paola Omedè, Philip Campbell, Anna Marina Liberati, Massimo Offidani, Roberto Ria, Stefano Pulini, Francesca Patriarca, Roman Hajek, Andrew Spencer, Mario Boccadoro, Antonio Palumbo
| Article suivant Article suivant
  • Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data
  • Didier Meulendijks, Linda M Henricks, Gabe S Sonke, Maarten J Deenen, Tanja K Froehlich, Ursula Amstutz, Carlo R Largiadèr, Barbara A Jennings, Anthony M Marinaki, Jeremy D Sanderson, Zdenek Kleibl, Petra Kleiblova, Matthias Schwab, Ulrich M Zanger, Claire Palles, Ian Tomlinson, Eva Gross, André B P van Kuilenburg, Cornelis J A Punt, Miriam Koopman, Jos H Beijnen, Annemieke Cats, Jan H M Schellens

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.

Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.